Humana (NYSE:HUM) Lowered to Hold Rating by Wall Street Zen

Humana (NYSE:HUM) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other analysts also recently issued reports about the stock. Truist Financial set a $280.00 price objective on shares of Humana and gave the company a “hold” rating in a report on Tuesday, June 17th. Barclays set a $268.00 price objective on shares of Humana and gave the company an “equal weight” rating in a report on Thursday, June 12th. Mizuho boosted their target price on shares of Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a research note on Wednesday, April 9th. Guggenheim initiated coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a “buy” rating and a $326.00 target price for the company. Finally, Bank of America decreased their target price on shares of Humana from $320.00 to $260.00 and set a “neutral” rating for the company in a research note on Tuesday, June 17th. Seventeen analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $280.76.

Humana Stock Down 0.8%

NYSE:HUM opened at $230.38 on Friday. The company has a market cap of $27.80 billion, a PE ratio of 16.29, a P/E/G ratio of 1.75 and a beta of 0.44. Humana has a twelve month low of $212.45 and a twelve month high of $406.46. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71. The company’s 50 day moving average is $237.78 and its two-hundred day moving average is $258.31.

Humana (NYSE:HUM) last released its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. Humana’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $7.23 EPS. Analysts anticipate that Humana will post 16.47 EPS for the current year.

Institutional Investors Weigh In On Humana

Hedge funds have recently modified their holdings of the business. denkapparat Operations GmbH acquired a new stake in shares of Humana in the fourth quarter valued at about $323,000. Allstate Corp acquired a new stake in shares of Humana in the fourth quarter valued at about $905,000. Deutsche Bank AG raised its position in shares of Humana by 18.2% in the fourth quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider’s stock valued at $160,185,000 after buying an additional 97,071 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Humana in the first quarter valued at about $1,309,000. Finally, Fred Alger Management LLC acquired a new stake in shares of Humana in the fourth quarter valued at about $451,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.